Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) TrialDiabetes Obes Metab 2022 Jan 10;[EPub Ahead of Print], O Lavynenko, M Abdul-Ghani, M Alatrach, C Puckett, J Adams, S Abdelgani, N Alkhouri, C Triplitt, GD Clarke, JA Vasquez, J Li, E Cersosimo, A Gastaldelli, RA DeFronzo
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.